Savient Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Savient Pharmaceuticals ( SVNT) is a biopharmaceutical company with one meaningful drug, Krystexxa, which treats chronic gout refractory to conventional therapy. This stock closed up 6.2% to $0.67 in Tuesday's trading session.

Tuesday's Range: $0.64-$0.68
52-Week Range: $0.51-$2.95
Tuesday's Volume: 743,000
Three-Month Average Volume: 793,930

>>4 Stocks Spiking on Unusual Volume

From a technical perspective, SVNT surged higher here back above its 50-day moving average of 65 cents with decent upside volume. This stock recently formed a double bottom chart pattern at 57 cents to 56 cents per share. Following that bottom, shares of SVNT have started to uptrend and approach a near-term breakout trade. That trade will hit if SVNT manages to take out some near-term overhead resistance at 75 cents with high volume.

Traders should now look for long-biased trades in SVNT as long as it's trending above its 50-day at 65 cents or above more support at 60 cents and then once it sustains a move or close above 75 cents with volume that hits near or above 793,930 shares. If that breakout hits soon, then SVNT will set up to re-test or possibly take out its next major overhead resistance levels at 90 cents to 91 cents per share. Any high-volume move above those levels will then put its 200-day at 94 cents to $1 into range for shares of SVNT.

If you liked this article you might like

Athersys (ATHX) Strong On High Relative Volume Today

Should You Buy Into Athersys’ Latest Spin on Failed Stroke Therapy?

Here’s Why Athersys (ATHX) Stock is Jumping Today

Athersys (ATHX) Stock Advances on Healios Licensing Agreement

5 Breakout Stocks Under $10 Set to Soar